XSTO
LARK
Market cap4mUSD
Oct 30, Last price
2.32SEK
1D
1.31%
1Q
4.50%
Jan 2017
-94.46%
IPO
-97.80%
Name
Combigene AB
Chart & performance
P/E
—
P/S
140.92
EPS
—
Vol. 1Y
49.88%
Shs. 5Y
46.15%
Rev. 5Y
-53.49%
Div Yld LY
8.62%
Div Yld TTM
86.21%
Revenues
326k
-94.12%
Net income
-45m
L+25.83%
CFO
-30m
L-1.99%
Dividend
May 08, 20262 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in its pipeline. CG01, a treatment targeting epilepsy, is undergoing preclinical trials that include detailed biodistribution and toxicology assessments. Its second candidate, CGT2, is under development for addressing lipodystrophy. CombiGene also maintains strategic alliances, including a licensing and collaborative agreement with Lipigon Pharmaceuticals AB to create a gene therapy for partial lipodystrophy, and a partnership with Spark Therapeutics for the advancement of adeno-associated virus (AAV) based gene therapies.
Key people
Robert Klatzkow
Chairman of the Board · since 2025
Luca Di Stefano
Interim Chief Executive Officer, Executive Director · since 2025
Louise Aspenberg
Chief Financial Officer · since 2020
Annika Ericsson
Chief Scientific Officer · since 2024
Susana Ayesa Alvarez
Director · since 2017
Alexander Gradin
Director · since 2025
Marcus Isaksson
Director · since 2024
Peter Nilsson
Director · since 2014
Lars Thunberg
Director · since 2006
Headquarters & legal address
Nybrogatan 7
Stockholm 114 34
SE
Stockholm 114 34
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||